IPL 550260

Drug Profile

IPL 550260

Alternative Names: IPL 550,260

Latest Information Update: 01 Jun 2007

Price : $50

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Anti-inflammatories
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Inflammation

Most Recent Events

  • 17 Mar 2006 Suspended - Phase-I for Inflammation in Canada (PO)
  • 13 Jul 2004 Inflazyme has completed phase Ib studies in inflammation in Canada
  • 25 Feb 2004 IPL 550260 is available for licensing worldwide (http://www.inflazyme.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top